When fat, muscle, and bone deteriorate simultaneously in older adults, the compounding effect on frailty and fracture risk is far greater than any single tissue loss alone. Understanding what coordinates this triple failure may be the key to interrupting it early — and a new theoretical framework published in Frontiers in Immunology proposes a unifying immune-metabolic explanation that reframes visceral adiposity not as passive storage tissue but as an active immunological driver of systemic organ decline.
The framework centers on osteosarcopenic obesity (OSO), a syndrome defined by the co-occurrence of osteoporosis or osteopenia, sarcopenia, and excess body fat. The proposed mechanism involves visceral adipose tissue functioning as a pro-inflammatory endocrine organ, continuously secreting cytokines, adipokines, lipotoxic mediators, and damage-associated molecular patterns (DAMPs). A particularly novel element is the emphasis on trained immunity — epigenetic and metabolic reprogramming of innate immune cells and their bone marrow progenitors — which effectively installs a persistent inflammatory memory that amplifies cross-tissue immune signaling. In skeletal muscle, this environment activates NF-κB catabolic pathways while suppressing mTOR-driven anabolic signaling, resulting in impaired protein homeostasis, fibrosis, and fat infiltration. In bone, senescence-associated secretory phenotype (SASP) signals converge on osteoclastogenic cascades, accelerating resorption and undermining structural integrity.
This integrative model is theoretically compelling because it offers a mechanism — trained immunity — that could explain why chronic low-grade inflammation persists even when precipitating triggers are removed, something prior osteoporosis and sarcopenia research has struggled to address. However, this is a conceptual framework paper, not a clinical trial or prospective cohort study, which means causal directionality remains unconfirmed in humans. The diagnostic heterogeneity the authors themselves acknowledge — varying OSO definitions and population-specific cut-offs — also limits direct translation to clinical risk tools. Still, the identification of innate immune epigenetic memory as a potential pharmacological or nutritional target (e.g., via senolytics or trained immunity modulators) represents a genuinely forward-looking contribution to geroscience research.
